Relief Therapeutics Holding AG operates as a biopharmaceutical firm, dedicated to providing vital therapeutic relief to patients suffering from severe diseases for which current medical solutions are insufficient. The company's reach extends across Switzerland, the broader European continent, North America, and various international markets. Its strategic focus is on advancing clinical-stage programs that leverage molecules with a proven history of clinical application. These programs are supported by either initial evidence of human biological activity or efficacy, or a strong scientific rationale. A key asset in their development pipeline is RLF-100, also known as aviptadil. This synthetic human vasoactive intestinal peptide (VIP) acts through diverse mechanisms, making it effective for a range of respiratory conditions. RLF-100 is currently undergoing Phase 3 clinical trials for treating acute respiratory distress syndrome and moderate-to-severe lung injury caused by COVID-19. Furthermore, it is in Phase 1 trials for managing acute lung injury in other intensive care unit settings, and in Phase 2 trials for addressing pulmonary sarcoidosis. Beyond RLF-100, Relief Therapeutics is also progressing with ACER-001, a distinct powder formulation of sodium phenylbutyrate. This compound has successfully completed Phase 3 trials for urea cycle disorders and is presently in Phase 1 for maple syrup urine disease. Additionally, the company is developing APR-TD011, a sprayable hypotonic acid-oxidizing solution, which is in Phase 2 development for the treatment of epidermolysis bullosa. Established in 2013, the company's main operations are based in Geneva, Switzerland.